Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers

Journal of the National Cancer Institute

Volumn 91, Issue 17, 1999, Pages 1475-1479

  Rebbeck, Timothy R ^a   Levin, Albert M ^b   Eisen, Andrea ^a   Snyder, Carrie ^c   Watson, Patrice ^c   Cannon Albright, Lisa ^d   Isaacs, Claudine ^e   Olopade, Olofunmilayo ⁱ   Garber, Judy E ^f   Godwin, Andrew K ^g   Daly, Mary B ^g   Narod, Steven A ^h   Neuhausen, Susan L ^d   Lynch, Henry T ^c   Weber, Barbara L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

^c CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF UTAH   (United States)

^e GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g FOX CHASE CANCER CENTER   (United States)

^h WOMEN S COLLEGE HOSPITAL   (Canada)

ⁱ 904 Blockley Hall ^*

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE;

ARTICLE; BREAST CANCER; CANCER CONTROL; CANCER RISK; CONTROLLED STUDY; FEMALE; GENE MUTATION; HORMONE ACTION; HUMAN; MAJOR CLINICAL STUDY; OVARIECTOMY; PRIORITY JOURNAL;

EID: 0033199926     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.17.1475     Document Type: Article

References (16)

1. Burke W, Daly M, Gurher J, Botkin J, Kahn MJ, Lynch P, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 1997;277:997-1003.
2. Piver MS, Jishi MF, Tsukada Y, Nava G. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Family Ovarian Cancer Registry. Cancer 1993; 71:2751-5.
3. Struewing JP, Watson P, Easton DF, Ponder BA, Lynch HT, Tucker MA. Prophylactic oophorectomy in inherited breast/ovarian cancer families. J Natl Cancer Inst Monogr 1995;17: 33-5.
4. Brinton LA, Schairer C, Hoover RN, Fraumeni JF Jr. Menstrual factors and risk of breast cancer. Cancer Invest 1988; 6:245-54
5. Meijer WJ, van Lindert AC. Prophylactic oophorectomy. Eur J Obstet Gynecol Reprod Biol 1992;47:59-65.
6. Parazzini F, Braga C, La Vecchia C, Negri E, Acerhoni S, Franchesi S. Hysterectomy, oophorectomy and premenopause, and risk of breast cancer. Obstet Gynecol 1997;90:453-6.
7. Schairer C, Persson I, Falkeborn M, Naessen T, Troisi R, Brinton LA. Breast cancer risk associated with gynecologic surgery and indications for such surgery. Int J Cancer 1997;70: 150-4.
8. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J Am Stat Assoc 1989;84:1074-8.
9. Barrett-Connor E. Hormone replacement therapy. BMJ 1998;317:457-61.
10. Gayther SA, Mangion J, Russell P, Seal S, Barfoot R, Ponder BA, et al. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet 1997;15:103-5.
11. Gayther SA, Warren W, Mazoyer S, Russell PA, Harrington PA, Chiano M, et al. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet 1995;11:428-33.
12. Mattingly RF. TeLinde's operative gynecology. 6th ed. Philadelphia (PA): Lippincott; 1985.
13. Kovac SR, Cruikshank SH. Guidelines to determine the route of oophorectomy with hysterectomy. Am J Obstet Gynecol 1996;175: 1483-8.
14. Colditz GA, Willett WC, Stampfer JM, Rosner B, Speizer FE, Hennekens CH. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987;316:1105-10.
15. Prior JC, Vigna YM, Wark JD, Eyre DR, Lentle BC, Li DK, et al. Premenopausal ovari-ectomy-related bone loss: a randomized. double-blind, one-year trial of conjugated estrogen or medroxyprogesterone acetate. J Bone Miner Res 1997;12:1851-63.
16. Lerman C, Hughes C, Lemon S, Main D, Narod S, Lynch H. Outcomes study of BRCA1/2 testing in members of hereditary breast ovarian cancer families. Proc ASCO 1997. p. 25.